Table 3: rSBA-MenC, rSBA-MenY antibody responses after Hib-MenCY-TT vaccination.

ReferenceVaccine dose 1–3Vaccine dose 4Timepoint 𝑁 rSBA ≥ 1 : 8rSBA ≥ 1 : 128GMT
%[95% CI]%[95% CI]Value[95% CI]

rSBA-MenC

Habermehl et al., 2010 [68] 2, 3, 4 + 12–18 months of ageHib-MenCY-TT + DTPa-HBV-IPVHib-MenCY-TT + DTPa-HBV-IPVPD370100[94.9–100]95.7[88.0–99.1]1005.8[773.5–1308.0]
Pre-D44691.3[79.2–97.6]63.0[47.5–76.8]153.1[90.4–259.4]
PD440100[91.2–100]100[91.2–100]4762.6[3427.5–6617.7]
MenC-CRM197 + DTPa-HBV-IPV/HibMenC-CRM197 + DTPa-HBV-IPV/HibPD371100[94.9–100]100[94.9–100]3557.6[2978.8–4248.8]
Pre-D44295.2[83.8–99.4]69.0[52.9–82.4]199.2[129.6–306.2]
PD439100[91.0–100]100[91.0–100]11819.3[8458.6–16515.2]

Nolan et al., 2007 [81] 2, 4, 6 + 11–14 months of ageHib-MenCY-TT + DTPa-HBV-IPVMen-PS ChallengePD374*100[94.8–100]98.6[92.2–100]1293.1[1027.7–1627.1]
Pre-Ch80*97.4[90.8–99.7]78.9[68.1–87.5]265.5[197.8–356.3]
Post-Ch73*100[94.8–100]98.6[92.2–100]1985.5[1542.6–2555.8]
MenC-CRM197 + DTPa-HBV-IPV/HibMen-PS ChallengePD377*100[95.1–100]98.6[92.7–100]1931.9[1541.2–2421.6]
Pre-Ch81*90.8[81.9–96.2]64.5[52.7–75.1]176.6[117.9–264.4]
Post-Ch79*97.5[91.2–99.7]84.8[75.0–91.9]774.8[536.7–1118.5]

Nolan et al., 2011 [84] 2, 4, 6 + 12–15 months of ageHib-MenCY-TT + 7vCRM + DTPa-HBV-IPVHib-MenCY-TT + MMR + VARPD328799.0[97.0–99.8]94.4[91.1–96.8]805[700–925]
Pre-D449590.7[87.8–93.1]48.7[44.2–53.2]103[90.1–117]
PD449699.6[98.6–100]97.2[95.3–98.4]1697[1516–1900]
MenC-CRM197 + Hib-TT + 7vCRM + DTPa-HBV-IPVHib-MenCY-TT + MMR + VARPD399100[96.3–100]96.0[90.0–98.9]790[649–961]
Pre-D416984.6[78.3–89.7]29.6[22.8–37.1]53.7[43.0–67.1]
PD416295.7[91.3–98.2]71.0[63.3–77.8]262[204–336]

rSBA-MenY

Habermehl et al., 2010 [68] 2, 3, 4 + 12–18 months of ageHib-MenCY-TT + DTPa-HBV-IPVHib-MenCY-TT + DTPa-HBV-IPVPD36997.1[89.9–99.6]92.8[83.9–97.6]470.7[351.1–631.2]
Pre-D44586.7[73.2–94.9]60.0[44.3–74.3]103.2[64.6–164.9]
PD440100[91.2–100]100[91.2–100]1708.1[1313.3–2221.4]

Nolan et al., 2007 [81]
2, 4, 6 + 11–14 months of age
Hib-MenCY-TT + DTPa-HBV-IPVMen-PS ChallengePD374*98.5[92.0–100]95.5[87.5–99.1]843.5[640.1–1111.7]
Pre-Ch80*89.2[79.8–95.2]60.8[48.8–72.0]114.7[80.0–164.4]
Post-Ch73*100[94.7–100]100[94.7–100]1838.0[1427.9–2366.0]

Nolan et al., 2011 [84]
2, 4, 6 + 12–15 months of age
Hib-MenCY-TT + 7vCRM + DTPa-HBV-IPVHib-MenCY-TT + MMR + VARPD328899.7[98.1–100]91.7[87.9–94.6]728[636–835]
Pre-D451498.4[97.0–99.3]80.5[76.9–83.9]264[241–290]
PD4496100[99.3–100]99.4[98.2–99.9]1987[1826–2161]

𝑁 : numbers of subjects with available data, * 𝑁 : numbers of subjects in the ATP Cohort, %: percentage of subjects with titre within the specified range, 95% CI: 95% confidence interval, GMT: Geometric Mean Titre, PD3: one month after dose 3 (ATP Cohort for Immunogenicity), Pre-D4: just prior dose 4 (ATP Cohort for Persistence), PD4: one month after dose 4 (ATP Cohort for Immunogenicity), Pre-Ch: just prior to meningococcal polysaccharide challenge (ATP Cohort for safety challenge phase), Post-Ch: one month after meningococcal polysaccharide challenge (ATP Cohort for Immunogenicity), Results of this table were previously published [68, 81, 84].